1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F3C661EC71BC9EF400258AD9003264ED
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-rare-disease-field-medical-excellence-north-america-establishing-standards-high-performance-impact?opendocument
18
19opendocument
2034.236.191.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Benchmarking Rare Disease Field Medical Excellence in North America: Establishing Standards for High Performance & Impact

ID: 5795


Features:

10 Info Graphics

14 Data Graphics

110+ Metrics

7 Narratives


Pages/Slides: 29


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Benchmarking Rare Disease Field Medical Excellence in North America: Establishing Standards for High Performance & Impact”

STUDY OVERVIEW

The rare disease market in North America represents a challenging yet promising landscape, characterized by a diverse array of conditions and a growing patient population in need of specialized care. Amidst a myriad of stakeholders, including influential key opinion leaders and healthcare providers, optimizing the efficiency of field medical teams becomes essential for rare disease manufacturers.

Best Practices, LLC undertook this benchmarking research to establish standards for high field medical performance and impact in North America's rare disease market. Our study provides strategic insights tailored to enhance KOL interactions, assess MSL performance, and strategically align staffing footprints.


KEY TOPICS

  • Effective Rare Disease Field Performance Metrics in North America
  • Building a Rare Disease Field Medical Excellence Framework
  • Target and Engagement Levels of Rare Disease KOLs in North America
  • Average Time Spent by Rare Disease MSLs on KOL Interactions and Internal Activities in North America
  • Rare Disease Field Medical Staffing Footprint in North America
  • Key Insights and Lessons Learned for Measuring the Impact of Rare Disease MSLs in North America

KEY METRICS

  • North America field scorecard: Benchmarking rare disease engagements
  • Average total panel size supported by an individual rare disease MSL in North America
  • Average number of monthly KOL/HCP and F2F meetings in North America – Rare disease segment
  • Value assigned to each interaction type on the rare disease MSL scorecard (North America)
  • Engagement metrics for non-tiered rare disease KOLs in North America
  • Average annual field presence of rare disease MSLs in North America
  • Time spent by rare disease MSLs on external, internal, and logistics activities in North America
  • Weekly rare disease MSL time allocation across activity streams in North America
  • Rare disease MSL engagement mix in North America
  • Rare disease field medical staffing footprint in North America

SAMPLE KEY FINDINGS

  • Rare Diseases Engagement Mix in North America: Rare Diseases MSLs in North America focus most (69%) of their interactions on KOL engagements, with the rest spent on HCPs (22%), payers, and other healthcare providers.

METHODOLOGY

Best Practices, LLC collated performance data and insights from field medical executives from rare disease companies around the world through a custom benchmark survey. Focused on rare disease field medical operations in North America, the research drew insights from a diverse range of respondents.


Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks for maximal alignment with varied portfolio considerations.

The final study draws on 448 survey responses, representing a benchmark class of over 100 biopharma manufacturers.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.